Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.31 |
| ▸ | ACACB | O00763 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456838 | 0.91 | ACACB (0.33) | PTGESSLC5A1SLC5A2ACACB | |
| SCHEMBL2866955 | 0.88 | CA1 (0.32) | CA1CA2TSHRACACB | |
| SCHEMBL2874526 | 0.86 | APP (0.30) | ACACB | |
| SCHEMBL2866046 | 0.78 | ACACB (0.33) | ACACB | |
| SCHEMBL1457124 | 0.77 | ACACB (0.38) | ACACB | |
| SCHEMBL4594430 | 0.76 | ENPP2 (0.44) | CA1CA2TSHR | |
| SCHEMBL1457449 | 0.75 | LMNA (0.40) | ACACB | |
| SCHEMBL1457067 | 0.70 | TAAR1 (0.39) | PTGES | |
| SCHEMBL2865494 | 0.70 | ENPP2 (0.38) | CA1CA2 | |
| SCHEMBL1539252 | 0.69 | SLC5A2 (0.49) | SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847074-B2 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | UGGT1, B3GAT3, UGCG | PTGES 1075/4885CA1 3750/4885CA2 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.